In patients with NSCLC carrying EGFR mutations, first‐generation TKIs such as gefitinib [216] and erlotinib [217] substantially extend PFS and increase the objective response rate (ORR) by competitively inhibiting the ATP binding site of EGFR. Here, EGFR is linked to non-small cell lung carcinoma.